Evotec OAI to Present at the BIO CEO and Investor Conference HAMBURG, Germany, Feb. 20 /PRNewswire-FirstCall/ -- Evotec OAI, a leading partner for integrated high-value-added drug discovery and development to the pharmaceutical and biotechnology industries, today announced that Joern Aldag, President and CEO of Evotec OAI, will present at the BIO CEO & Investor Conference on Tuesday, 24 February 2004 at 02:30 p.m. ET at the Waldorf-Astoria, 301 Park Avenue, New York. A webcast will be available -live and on demand - at http://www.firstcallevents.com/service/ajwz400591551gf12.html. About Evotec OAI AG Evotec OAI has established itself as the partner of choice for drug discovery and development services for pharmaceutical and biotechnology companies worldwide, maintaining its leadership role through innovation and unmatched customer service. The Company's business strategy is clearly focussed on drug discovery. It has established the most comprehensive technology platform and skills that integrate its world-class biology and chemistry capabilities. Evotec OAI leverages this discovery engine in providing assay development and screening through to compound optimisation and drug manufacturing services to a broad and well-established networkof customers. In addition, the Company engages in selected discovery programmes itself to develop drug candidates for early out-licensing. Evotec OAI's instrument and technology business is now successfully handled by its affiliate, Evotec Technologies. With over 600 people in Hamburg, Germany and Oxfordshire, UK, Evotec OAI is dedicated to returning value to its shareholders and employees through a sustainable business strategy that balances short-term and long-term revenue opportunities. http://www.firstcallevents.com/service/ajwz400591551gf12.htmlDATASOURCE: Evotec OAI CONTACT: Anne Hennecke of Evotec OAI AG, +49-40-56081-286,

Copyright